HOME >> BIOLOGY >> NEWS
New antimalarial combination confirms its potential use in treating drug-resistant malaria

Yaound, Cameroon, 15th November 2005 Clinical results demonstrating the potential benefits of treating Plasmodium falciparum malaria with a new artemisinin-based combination therapy (ACT), chlorproguanil hydrochloride-dapsone-artesunate (CDA)1, were announced today at the 4th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Cameroon. CDA is being developed to meet the urgent need for new malaria treatments for Africa where drug resistance is contributing to an escalating health crisis. Dr. Arata Kochi, Director of the WHO Roll Back Malaria (RBM) Department stated, "The effort to develop CDA responds to RBM's call for fixed-dose artemisinin containing combinations."

The phase II trial of CDA, involving adults and children with P. falciparum malaria, was designed to determine the optimum dose of artesunate in combination with LapdapTM (chlorproguanil/dapsone). Treatment with CDA, at three doses of artesunate (1, 2 and 4mg/kg) in adults and at two doses (2 and 4mg/kg) in children, led to faster time to reduce parasite levels in the blood by 90 percent when compared to treatment with Lapdap alone.1 Reductions in parasite viability and potential parasite reproductive ability in patients were also greater in those treated with CDA than Lapdap alone. All treatment doses of CDA were generally well tolerated, and the nature and incidence of adverse events were similar across treatment groups.1

"These results suggest that CDA could become a major weapon in the fight against drug-resistant malaria. Moving into phase III trials marks a key step in the development of this promising antimalarial," commented Dr. Chris Hentschel, CEO of MMV.

Phase III trials for CDA are planned across sub-Saharan Africa and will further study the safety and efficacy of treating P. falciparum malaria with CDA. One study will compare CDA against the only fixed-dose ACT currently available for the treatment of P. falciparum, artemether/lumefantrine, over a
'"/>


15-Nov-2005


Page: 1 2

Related biology news :

1. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
2. Research milestone brings goal closer of cheap antimalarial drug for developing world
3. $43 million from Gates Foundation to produce inexpensive antimalarial drug for Third World
4. Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer
5. New study suggests promising drug combinations for sleeping sickness
6. Recombination protein dynamics observed with single monomer resolution
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New combination treatment induces regression of prostate cancer
9. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
10. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants
11. Pesticide combinations imperil frogs, probably contribute to amphibian decline

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... -- Research and Markets has announced the addition of ... their offering. The report forecasts ... grow at a CAGR of 12.28% during the period 2016-2020. ... market analysis with inputs from industry experts. The report covers the ... report also includes a discussion of the key vendors operating in ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
Breaking Biology Technology:
Cached News: